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Summary:  
Anti-capsular pneumococcal antibody concentrations associated with protection against carriage 
vary between serotypes and are higher than antibody levels required for protection against disease. 
Higher antibody concentrations are required for protection in lower-income countries.
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Abstract 
Background 
Pneumococcal conjugate vaccines (PCVs) provide direct protection against disease in those 
vaccinated, and interrupt transmission through the prevention of nasopharyngeal carriage. 
Methods 
We analysed immunogenicity data from 5224 infants who received PCV in prime-boost schedules. 
We defined any increase in antibody between the one-month post-priming visit and the booster 
dose as an indication of nasopharyngeal carriage (‘seroincidence’).   
We calculated antibody concentrations using receiver-operator characteristic curves, and used 
generalised additive models to compute their protective efficacy against seroincidence. 
To support seroincidence as a marker of carriage, we compared seroincidence in a randomised 
immunogenicity trial in Nepal with the serotype-specific prevalence of carriage in the same 
community.  
Findings 
In Nepalese infants, seroincidence of carriage closely correlated with serotype-specific carriage 
prevalence in the community.   
In the larger data set, antibody concentrations associated with seroincidence were lowest for 
serotypes 6B and 23F (0.50 µg/mL and 0.63 µg/mL respectively), and highest for serotypes 19F and 
14 (2.54 µg/mL and 2.48 µg/mL respectively). The protective efficacy of antibody at these levels was 
62% and 74% for serotypes 6B and 23F, and 87% and 84% for serotypes 19F and 14. 
Protective correlates were on average 2.15 times higher in low/lower middle income countries than 
in high/upper middle income countries (GMR 2.15, 95%CI 1.46–3.17, p=0.0024). 
Interpretation 
Antibody concentrations associated with protection vary between serotypes. Higher antibody 
concentrations are required for protection in low-income countries. These findings are important for 
global vaccination policy, to interrupt transmission by protecting against carriage. 
Downloaded from https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/cix895/4560783
by St George's University of London user
on 10 November 2017
 3 
 
Introduction 
Vaccination with pneumococcal conjugate vaccines (PCV) induces IgG antibody production which 
peaks approximately one month after vaccination and wanes thereafter in the absence of serotype-
specific exposures1. The concentration of circulating serum antibody that is sufficient to protect an 
infant against invasive pneumococcal disease (IPD) or nasopharyngeal colonisation during the post-
vaccination period is not well defined but is generally higher for mucosal endpoints than IPD and 
varies between serotypes.2-4  
In large efficacy trials only a small proportion of children will have antibody concentrations assessed 
after vaccination, precluding analyses which directly link the antibody concentration in an individual 
with their disease outcome. In such situations the overall trial-level estimates of the proportion with 
disease and the proportions with antibody below a threshold level are used to define an antibody 
level associated with protection which is referred to as a correlate of protection.5-7 A pooled 
correlate of protection against IPD of 0.35 µg/mL was derived from a meta-analysis of three efficacy 
trials68-10 Although these thresholds have provided a means to establish licensure of additional 
products, they cannot predict protection for the individual, as evidenced by a case report of vaccine 
failure in a 9-month old child, 10 days after a measured antibody concentration of 4.98 µg/mL.11  
Current correlates of protection refer only to protection against IPD, and not to other endpoints of 
clinical importance such as acute otitis media, non-bacteraemic pneumonia, nor to nasopharyngeal 
carriage. The effector molecule for protection against mucosal colonisation is unlikely to be 
circulating serum IgG, but instead may be IgG or IgA that is produced by mucosally associated B-
cells, or IgG which leaks from circulation to mucosa.12,13  Nevertheless, circulating serum IgG 
concentrations measured 4-6 weeks post-vaccination can serve as a proxy for the level of immune 
response to pneumococcal conjugate vaccines which in turn provides protection from carriage. Since 
nasopharyngeal colonisation is a necessary precondition for development of pneumococcal disease 
and is the mechanism for transmission of pneumococcal infection, vaccine efficacy against this 
endpoint is key to preventing disease reducing transmission, inducing herd immunity, and thereby 
delivering maximum health benefits of PCV.14,15 
The aim of this study was to use a large number of vaccine trials with individual participant level data 
to calculate the concentration of serotype-specific serum IgG which is associated with protection 
against nasopharyngeal colonisation in the individual.   
Methods 
Data 
Individual level serological data were sought from immunogenicity clinical trials in which PCV was 
administered to children in prime-boost schedules. Blood samples were taken for serology at one-
month post-priming and at the booster dose visit. For each participant, antibody concentrations 
were compared at the one-month post-priming visit and the booster visit. Any increase in antibody 
at the latter time-point was considered evidence for natural boosting due to pneumococcal carriage 
acquisition at some point in the intervening period (‘seroincidence’).  
Downloaded from https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/cix895/4560783
by St George's University of London user
on 10 November 2017
 4 
 
Randomised Trial in Nepal 
Additional immunogenicity data were available from an open-label randomised controlled trial of 
10-valent PCV (PCV10) in Nepal (authors own data). Details of the trial have been previously 
published16 (Supplementary material).  
Antibody concentrations have been shown to increase after nasopharyngeal carriage.17 To confirm 
that any increase in antibody between two time points is a good proxy measure for nasopharyngeal 
colonisation with the same serotype, antibody data from the Nepal RCT were paired with data from 
a cross-sectional carriage study of 600 healthy children (aged 6 weeks to 24 months) conducted 
during the same period and the same study centre.18 High correlation between the proportions of 
children with an increase in antibody levels between the pre-boost and post-primary time points, 
and the proportions of community children with positive nasopharyngeal swabs was considered 
supportive evidence for the use of seroincidence as a marker of nasopharyngeal carriage.  
Use of carriage seroincidence to define antibody thresholds of protection 
Two methods were used to analyse the association between serotype-specific pneumococcal serum 
antibody concentrations and seroincidence. 
First, serotype-specific receiver-operator characteristic (ROC) curves were created for antibody 
measured one-month post-priming vaccination, compared with seroincidence in the following 
months prior to the booster dose visit (see Supplementary material, Table S1 and Figure S1). From 
each ROC curve, the antibody level which maximised the sum of sensitivity + specificity was retained 
as the antibody level most able to discriminate between those with and without presumed carriage 
acquisition in the post-vaccination period.19,20  
A second analysis used generalised additive models (GAM) to compute the protective efficacy of the 
antibody thresholds identified from ROC curves. A GAM model for binary data using seroincidence as 
the outcome was applied to each country cohort and serotype separately, with IgG at one-month 
post-priming fitted with a spline smooth. The models adjusted for age and sex. For each country 
cohort the antibody concentration at which the probability of seroincidence became negligible 
(probability < 0.05) was identified.  
The probability of seroincidence at the level of antibody identified from ROC curves was compared 
to the probability of seroincidence in those with antibody below the lower limit of assay 
quantification (LLD) to compute the protective efficacy of each ROC threshold. 
Protective thresholds from ROC curves were compared across income strata (high/upper middle 
income countries (H/UMIC) vs low/lower middle income countries (L/LMIC)) using mixed effects 
models. In addition, the proportion of infants with maternal antibody prior to vaccination was 
compared. Infants with antibody against pneumococcal serotypes prior to vaccination are likely 
indicative of mothers who had been susceptible, exposed and infected (likely with asymptomatic 
carriage) within a time period which enabled transplacental transfer of antibody to occur. The 
seroprevalence of type-specific pneumococcal antibodies in infants aged ~8 weeks is therefore 
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interpreted as a surrogate measure of the force of infection and its association with calculated ROC 
antibody thresholds was investigated.  
Sensitivity analyses were undertaken as detailed in the supplementary material, which contains 
further statistical methods. 
Results 
Antibody increase and circulating serotypes in the community 
There was a strong relationship (R2=0.743) between seroincidence in the immunogenicity trial 
participants in Nepal, and nasopharyngeal carriage prevalence among children in the same 
community as the trial participants. Because antibodies to some serotypes are cross-reactive to 
other serotypes within the same serogroup (vaccine-related types), it was unclear which serotype 
might be responsible for an observed antibody increase among the immunogenicity participants. For 
this reason, serotype data from nasopharyngeal carriage observations were combined into 
serogroups. With the exception of serotypes 1 and 5, confidence intervals for nasopharyngeal 
carriage included the line of best fit (Figure 1). 
Serotype-specific antibody thresholds of protection against seroincidence 
Pneumococcal IgG serum concentrations were available from 29 studies (19 countries, and 5224 
children). Studies were conducted in Europe (Denmark, The Czech Republic, Finland, France, 
Germany, The Netherlands, Poland, Slovakia, Spain, Sweden), Asia (India, Japan, Malaysia, Nepal, 
Philippines, and Singapore), Africa (Mali, Nigeria), and Chile (Table S2). 
Pneumococcal antibody thresholds of protection derived from ROC curves varied by serotype. The 
lowest threshold was 0.50 µg/mL and the highest was 2.54 µg/mL, for pneumococcal serotypes 6B 
and 19F antibodies respectively (Figure 2, Table 1).  
The probability of seroincidence from GAM models declined as antibody increased, until a point 
where the probability became negligible and curves flattened out (Figure 3). For serotype 1 the 
probability of seroincidence was low for all levels of post-primary antibody thus the point at which 
the probability became negligible could not be defined (Figure 3). For serotypes 4, 5, 7F and 18C, the 
post-primary antibody thresholds from both ROC and GAM methods were essentially the same, thus 
seroincidence is negligible for antibody above these levels. For the remaining serotypes (6B, 9V, 14, 
19F and 23F) antibody concentrations of at least 3.45 µg/mL were required to minimise 
seroincidence to the 5% level. However, substantial protection against seroincidence was available 
with antibody at levels of 0.50 to 2.54 µg/mL as defined by ROC curves, and protective efficacy 
estimates at these levels was between 62% and 87% (Table 1).  
High and low income countries 
Overall across all serotypes, thresholds derived from ROC curves were twice as high in L/LMICs, than 
in H/UMICs (GMR 2.15 95% CI 1.46–3.17, p=0.0024) although for individual serotypes confidence 
intervals overlapped (Figure 4). Seroprevalence of maternal antibodies in infants prior to vaccination 
was also higher in L/LMICs (p=0.0006), and there was a significant relationship between the 
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proportion of children with maternal antibody and the estimated correlate of protection for the 
same serotypes (p=0.0347) (Figure S2). 
Sensitivity analyses 
Sensitivity analyses showed that variations in the definition of seroincidence had little impact on 
calculated correlates of protection (Table S3).
Discussion 
This analysis of infant immunogenicity data from 5224 infants in 29 studies in 19 countries, 
estimates pneumococcal serotype-specific antibody concentrations associated with protection 
against an increase in antibody following the primary vaccination series, which we infer as a proxy 
for nasopharyngeal carriage. It confirms that more antibody is needed to protect against carriage 
than the current level of 0.35 mg/mL associated with protection against IPD. Dagan et al in a study of 
NP carriage acquisition report more than 80% of acquisitions occurred in children with antibody 
higher than 0.35 µg/mL one-month post-primary vaccination.4 All calculated antibody 
concentrations in our study were higher than serotype-specific correlates of protection previously 
derived for IPD, a finding also observed by Dagan.2,4  
The mechanism of protection against carriage is unclear but could be mediated by either IgA or IgG. 
IgA mediated immunity has been demonstrated in mice and levels of the isotype are typically lower 
than and proportional to systemic IgG levels.21 However, S. pneumoniae produces an IgA protease 
which may mean that local production of IgA at the mucosa is successfully evaded by 
pneumococci.22  It may be that higher blood levels of IgG correlate with local production of IgG at 
the mucosa or that high levels of circulating IgG leak across to the mucosal surface from the 
circulation and provide local protection against colonisation.13 
Relationship with circulating serotypes 
The serogroup-specific prevalence of nasopharyngeal carriage in unvaccinated healthy children in a 
cross-sectional carriage study in Nepal was closely associated with the proportions of children who 
had antibody increases in the PCV immunogenicity trial. The two studies were conducted in the 
same period and location, providing compelling, indirect, evidence of the validity of using serology to 
infer colonisation. For serotypes 1 and 5, the frequency of seroincidence was not closely associated 
with nasopharyngeal carriage prevalence in the community. There were no positive swabs for 
serotype 1, and only one for serotype 5 from 600 children tested, yet large proportions of children in 
the immunogenicity trial had antibody increases by 3 years of age for these serotypes. These 
serotypes appear to circulate more widely than is indicated by cross-sectional carriage studies, 
consistent with data showing a short half-life of colonisation, and rapid transmission.23 Serotypes 1 
and 5 are associated with the majority of invasive disease among young children in Nepal,18,24 
therefore serological methods may be better at assessing colonisation for these serotypes than 
nasopharyngeal swabs.  
Protective thresholds   
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Substantial variation exists in the level of antibody associated with protection against carriage, as 
potentially expressed by seroincidence.  Thresholds defined using ROC curves represent the 
antibody level which best distinguishes those who have greater levels of protection. 
Using ROC curves, the lowest correlates of protection (0.50 µg/mL and 0.63 µg/mL) were observed 
for serotypes 6B and 23F respectively, and the highest were 2.54 µg/mL and 2.48 µg/mL for 
serotypes 19F and 14. Andrews et al. calculated correlates of protection using IPD cases in UK 
children and found similar serotype-specific variation, with higher levels of antibody required for 19F 
and lower levels for 6B, and 23F.2 Similarly, Dagan et al report the antibody level above which 10% of 
carriage acquisitions occurred was high for serotypes 14 and 19F, and low for 23F, however 6B was 
also high in that study.4 These findings are consistent with in vitro evidence that more IgG is required 
to kill serotype 19F than 6B.25  
GAM thresholds can be interpreted as the level of antibody at which the probability of seroincidence 
becomes negligible (<5%). For serotypes 4, 5, 7F and 18C, the ROC and GAM thresholds were similar. 
For serotypes 6B, 9V, 14, 19F and 23F, much higher levels of antibody were consistent with a 
probability of seroincidence of 5% than those obtained from ROC curves, thus the ROC correlates for 
these serotypes indicate less than complete protection for the individual. Such difference may relate 
to a longer duration of carriage.26,27  
These antibody concentrations show similarities with thresholds derived for other mucosal 
endpoints. Our estimate of 0.50 µg/mL for serotype 6B derived using ROC methods, had a protective 
efficacy of 62%. This is very similar to the predicted vaccine efficacy (VE) of ≥ 65% against acute otitis 
media (AOM) at 0.5 µg/mL reported by Jokinen et al.28 Thus an antibody concentration of 0.5 µg/mL 
more than halves the probability of 6B carriage and the majority of protection occurs with induction 
of this small amount of antibody. In Dagan’s model of carriage acquisition rates which used similar 
regression model methodology, 0.5 µg/mL of antibody against serotype 6B equated to 
approximately 6.5% probability of acquisition in the Jewish cohort, and 13.5% acquisition in the 
Bedouin community. 10% of carriage acquisitions occurred in those with post-vaccination antibody 
of at least 7.4 or 10.8 µg/mL in the Jewish and Bedouin cohorts respectively.4 
In contrast, VE against serotype 23F AOM was negligible in Jokinen et al at 0.65 µg/mL with wide 
confidence intervals28 whereas in our analysis protective efficacy against colonisation was 74% at 
this antibody level. Millar et al investigated 17 cases of serotype 23F carriage acquisition after 
vaccination with PCV7 and report no carriers achieving serotype 23F antibody concentrations 
greater than 4 mg/mL before acquisition. This threshold value for total protection is slightly lower 
than the estimate from GAM analysis of 5.81 mg/mL (95%CI 4.64–7.28).29 In Dagan et al 10% of 
acquisitions occurred at antibody levels above 2.97 mg/mL. 
The probability of seroincidence predicted from GAM models for serotypes 9V, 14, 19F and 23F was 
between 10% and 22% for antibody at the level of the ROC thresholds. Thus these levels of antibody 
provide substantial protection even though not representing levels which provide absolute 
protection for an individual.  
High and low income countries 
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Protective antibody concentrations were on average twice as high in L/LMICs than in more wealthy 
countries. Carriage of pneumococci increases with factors such as household size, exposure to 
smoke (including from cooking fires), and underlying illnesses.30-32 Such factors are also related to 
socioeconomic status. Higher rates of nasopharyngeal colonisation in low income settings have been 
observed from carriage studies in young children32 and in rural settings compared with urban.31 
Dagan et al showed that the relationship between carriage acquisition rates and antibody levels can 
be quite different for high and low socioeconomic groups in a study of Jewish and Bedouin 
communities.4 Higher rates of colonisation in the community (i.e. higher force of infection) would 
increase the probability that such colonisation occurs during pregnancy, resulting in higher maternal 
antibody in early infancy. Seroprevalence of maternal antibodies is therefore a useful proxy for 
exposure. Our analysis shows the seroprevalence of maternal antibodies in infants (a surrogate for 
the force of infection) is higher in L/LMICs, and is significantly related to the antibody concentration 
required for protection against seroincidence for the same serotypes. The higher level of antibody 
needed for protection in L/LMICs may relate to a higher infectious load delivered at each 
nasopharyngeal exposure event, requiring higher levels of antibody for individual protection. In 
addition, the variation across serotypes in both force of infection and antibody levels required for 
protection indicates biological variation in characteristics of the bacteria resulting in varying abilities 
of serotypes of pneumococci to colonise the nasopharynx. 
Limitations and strengths 
Deriving robust thresholds of protection from any single study is problematic due to the large degree 
of variation between studies in both VE and estimated correlates of protection.2,6,8,10 The main 
strength of this analysis is therefore the uniquely large dataset of paired immunogenicity data in 
infants from a large number of studies. All results were assayed in one laboratory. This has the 
benefit of reducing the influence of inter-laboratory variation, however also means caution must be 
applied when extrapolating to results from other laboratories and other vaccines.  
The use of seroincidence as a proxy for carriage improves the detection of acquisition events as the 
data are not limited by the timing and frequency of nasopharyngeal swabs but instead create a 
historical record of the acquisition events experienced during the period between the post primary 
age and the booster age.  This improves the differential misclassification that affects cross-sectional 
carriage studies, however cannot remove it entirely. Misclassification of true carriage events in our 
data can be due to many reasons including (1) rises and then falls in antibody between blood draws 
resulting in an overall observed decline, or (2) rises in antibody from transient exposure but not a 
true carriage event. These data were not from studies designed to compute antibody thresholds and 
are speculative in nature. The lengths of time between priming and booster doses varied across 
studies which may affect misclassification rates and the thresholds calculated from the data.  
Conclusion 
The variation between serotypes in antibody levels which are associated with an inferred protection 
against carriage in this investigation support previous observations that combined correlates of 
protection for all serotypes are inaccurate for some serotypes.17 
Downloaded from https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/cix895/4560783
by St George's University of London user
on 10 November 2017
 9 
 
We recommend considering the use of serotype-specific thresholds of protection in clinical trials to 
demonstrate induction of antibody levels associated with high protection against colonisation to 
support vaccine development, dosing schedule optimization, and the assessment of vaccine impact.  
In settings with high force of infection, often low-income settings, higher levels of antibody are 
required to interrupt transmission. These findings are important for global vaccination policy 
especially with regard to assessment of alternative schedules aimed at reducing transmission to gain 
indirect effects (herd immunity) of the vaccine and maximizing the impact of the vaccine. 
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Tables and Figures  
Table 1  Serotype-specific pneumococcal antibody correlates of protection against seroincidence in infancy  
Serotype 
Protective 
antibody 
concentration 
(ROC) 
(µg/mL) 
LCL 
(µg/mL) 
UCL 
(µg/mL) 
Antibody 
concentration 
equivalent to 
5% 
seroincidence 
probability 
(GAM)* 
(µg/mL) 
LCL 
(µg/mL) 
UCL 
(µg/mL) 
Probability† of 
seroincidence at 
antibody level from ROC 
curves 
 (column 2) 
PE of ROC 
antibody threshold 
compared to 
antibody at the LLD 
1 0.81 0.54 1.22 N/A N/A N/A N/A N/A 
4 1.16 0.90 1.49 0.87 0.81 0.95 5% >90% 
5 0.73 0.42 1.26 0.62 0.42 0.90 5% >90% 
6B 0.50 0.40 0.61 5.35 4.01 7.14 33.1% 62% 
7F 1.60 1.25 2.05 1.73 1.53 1.95 5% >90% 
9V 1.31 1.08 1.58 3.45 2.90 4.11 12.4% 86% 
14 2.48 2.02 3.04 8.90 7.49 10.58 15.0% 84% 
18C 1.32 0.95 1.82 1.58 1.37 1.84 5% >90% 
19F 2.54 1.83 3.53 9.48 7.39 12.15 9.9% 87% 
23F 0.63 0.47 0.83 5.81 4.64 7.28 21.7% 74% 
Data are displayed in Figure 2. PE: protective efficacy, ROC: receiver operator characteristic curve method for derivation of correlates of protection, GAM: 
generalised linear model method for derivation of thresholds of protection, LLD: lower limit of assay detection, LCL: lower 95% confidence limit, UCL: upper 
95% confidence limit 
Protective efficacy is calculated as 1-(pr(ROC)/pr(LLD))x 100%.  
pr(ROC) is the probability of seroincidence predicted from GAM model at a level of antibody equivalent to the ROC correlate of protection.  
pr(LLD) is the probability of seroincidence predicted from GAM model at the lower limit of detection of the assay (0.05 mg/ml) 
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*Antibody level at which the probability of seroincidence is less than 5% 
†Predicted probability from GAM model 
For serotypes 4, 5, 7F and 18C ROC and GAM thresholds had substantially overlapping confidence intervals. The probability of seroincidence is considered 
to be the same (5%) for both methods. 
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Figure 1  The percentage of participants in a randomised PCV immunogenicity trial in Nepal 
with an increase in vaccine serotype IgG between 10 months and 3 years of age, and serogroup-
specific nasopharyngeal carriage prevalence in a cohort of healthy unvaccinated children from the 
same community.  
Dotted line represents the line of best fit from linear regression with intercept set at 0. There was no 
carriage of serotype 1 detected. 95% confidence intervals use the binomial exact method. 
Figure 2  Serotype-specific pneumococcal antibody correlates of protection against 
seroincidence in infancy 
Blue circles represent serotype-specific thresholds of protection against carriage derived from ROC 
curves and 95% confidence intervals. Red squares represent thresholds of protection and 95% 
confidence intervals from GAM models. For reference, grey bars are antibody correlates of 
protection for IPD from Andrews et al (reference 2) (not available for serotype 5). Data are also 
presented in Table 1. ROC: Receiver operator characteristic; GAM: generalised additive models; IPD 
invasive pneumococcal disease 
Figure 3 The relationship between the serotype-specific probability of seroincidence 
estimated from generalised additive models, and the antibody concentration measured one-
month after administration of 2 or 3 priming doses of pneumococcal conjugate vaccine   
Each dot represents one participant. Horizontal dashed lines at a probability of 0.05. 
Figure 4  Serotype-specific pneumococcal antibody correlates of protection in infancy 
stratified by income status of country setting.  
Serotype specific threshold correlates of protection and their 95% confidence intervals. Closed 
squares: Low or lower middle income countries (L/LMIC): India, Mali, Nepal, Nigeria, The Philippines; 
Open Squares: High or upper middle income countries (H/UMIC): Chile, Czech Republic, Denmark, 
Finland, France, Germany, Japan, The Netherlands, Norway, Poland, Singapore, Slovakia, Spain, 
Sweden.  L/LMIC vs H/UMIC: GMR 2.15, 95%CI (1.46–3.17), p=0.0024  
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